ArticleInvestigative ophthalmology & visual science2025
Reshaping the Burden of nAMD: National, Regional, and Global Prevalence of MNV3 and Its Correlation With Life Expectancy-The RAP Study, Report 7.
Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global research trends and hotspots in the pathophysiology, imaging and therapy of type 3 macular neovascularization (MNV3) in age-related macular degeneration (AMD).Frontiers in medicine · 2026Pooled it
- Fast nanoDSF Tear Fluid Profiling: Toward Diagnosis of Age-Related Macular Degeneration.Life (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To report the global distribution of macular neovascularization type 3 (MNV3) and to redefine the associated burden of neovascular age-related macular degeneration (nAMD). Methods: A total of 4652 patients with treatment-naïve nAMD were included. MNV3 was diagnosed using multimodal imaging methods. The prevalence of MNV3 in each country, region, continent and worldwide was calculated. The correlation between the prevalence of MNV3 and life expectancy in each country was estimated. Continent prevalence data was compared using a logistic (binomial) generalized linear mixed model (GLMM). Results: Our analysis revealed 4652 nAMD eyes from 47 countries, 575 (12.4%) of which had MNV3. In North America, the highest percentage was in Canada (17.6%), followed by the USA (11.5%). In Europe, the highest prevalence (23.4%) was in Austria and the lowest (4.3%) in Russia and Croatia. The prevalence in Asia, South America, and Australia was 6.6%, 9.4%, and 13.7%. A significant positive correlation was found between the MNV3 prevalence and life expectancy in 20 European countries (r = 0.63, P < 0.003). The GLMM revealed significantly lower odds for observing MNV3 in Asia compared to Europe (P < 0.01). No significant difference was observed in any other continent pair. The prevalence in Western Europe and Mediterranean region was higher than in Eastern Europe and the non-Mediterranean region (18.6% vs. 9.6%, P < 0.001; and 17.5% vs. 12.6%, P = 0.001, respectively). Conclusions: MNV3 is more prevalent in Western and Mediterranean regions, likely because of higher life expectancy and a lower percentage of Asian ethnicity. AREDS supplements and the Mediterranean diet may not provide prophylactic benefits against the development of MNV3. The unique distribution pattern of MNV3 and its correlation with life expectancy should be considered in nAMD research to ensure adequate representation of MNV3 patients in clinical trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.